(Date:10/13/2008)...Sixteen States and Washington, D.C., WASHINGTON, ...d Cross,today announced a new course. Coping With ...Families, is now available. The course, offered fr...f active duty, Reserve and,National Guard forces, ...,the course is offered in sixteen states (Ala., Ar...
(Date:10/13/2008)...ge Sharing among Physicians, MOUNTAIN VIEW, Calif...lysis of the healthcare IT market, Frost & Sulliva...merican Frost & Sullivan Award for,Technology Inno...Records,(EMR) version 4, featuring the Praxis(R) E... employs a unique technology that does not,include...
(Date:10/13/2008)...ined Energy Enhancing Supplement, BOCA RATON, Fla...,nutritional supplement manufacturer, introduces G... Glyc,n Go, is the first and only chewable form of...and the effects that it has on the,energy system h...iners,around the globe., In clinical trials, the ...
(Date:10/13/2008)...ire/ -- NeoVista, Inc., presented,yesterday the an...rachytherapy device on choroidal neovascular lesio...a Specialist,s (ASRS) 26th Annual Meeting. The,12-... of The Methodist,Hospital, Houston, Texas, demons...nd ocular coherence tomography (OCT) in many patie...
Breaking Medicine News(10 mins):Health News:American Red Cross Offering Free Class to Help Military Families Cope With the Stress of Deployments 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3...llapsed on a family in Karawal Nagar area of north...n and two adults and injuring four others on Satur... the wall of a school building, which had been con...uty commissioner of police R.L Meena said that the...
...inst cancer focusing at the molecular and genetic ...cerous cells is coming under increasing scrutiny./...na at Chapel Hill have demonstrated that these sup...the ultimate development and aggressiveness of can...
... University of Michigan and the Mayo Clinic say th...t not be very effective in women who inherit a com...gene has the ability to influence the levels of a ... tamoxifen against breast cancer. The study which ...
...are encouraging stereotype body images among their...he Florida State University. Even three year olds ...encouraged to eat well and grow physically,// whil...others were of the opinion that their daughters at...
Other Medicine News:Health News:Cancer Cells Trigger Supporting Cells to Turn Cancerous 2(Date:10/12/2008)...GTON, Oct. 12 /- Boston,Sci...results from an analysis,of nearly 7,500 patients ...e designed to confirm the performance of the TAXUS... System in real-world practice. The,two-year poole...clinical,restenosis in patients with diabetes as e...
(Date:10/10/2008)...- Boston Scientific,Corpora... the Company,s major,events and press announcement...) twentieth annual Transcatheter Cardiovascular Th...from October 12 to 17 in Washington, D.C., Boston...ety and,efficacy data on its TAXUS(R) Express2(TM)...
(Date:10/9/2008)...s Expected in November 2008, BOTHELL, Wash., Oct....mex: DDD ) announced today the completion of pati...ee pivotal trials to evaluate the safety and,effic... (ER) ibuprofen for,the over-the-counter (OTC) mar...s from this pivotal trial in November 2008. Ibupro...
(Date:10/8/2008)...nform Treatments for Spinal Cord, Other Nerve,Inju...re/ -- A protein that enables,nerve cells to commu...ling,the developing nervous system. Research into ... among nerve cells may provide a basis for eventua...heir nervous system,including spinal cord injury....
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2172 1Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2172 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2172 3Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update 2170 1TriWest Contributes 2475 000 to Agencies Supporting California Guardsmen 8177 1TriWest Contributes 2475 000 to Agencies Supporting California Guardsmen 8177 2TriWest Contributes 2475 000 to Agencies Supporting California Guardsmen 8177 3Vanda Presents Phase III Iloperidone Efficacy Data 1052 1Vanda Presents Phase III Iloperidone Efficacy Data 1052 2Vanda Presents Phase III Iloperidone Efficacy Data 1052 3Vanda Presents Phase III Iloperidone Efficacy Data 1052 4...s of Phase 2 Clinical Data Published at the Americ...g, CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -...ings from its Phase II,multi-center clinical stud...thetic anthracycline currently in development,for ...dings,indicate favorable interim results in terms ...
...s in Patients With Follicular Lymphoma Reported,To... 2007 /PRNewswire/ -- GlaxoSmithKline plc,announce...ial of a,single one-week course of frontline treat...umomab and Iodine I-131 Tositumomab) in,76 patient...gkin,s,lymphoma (NHL). This regimen was found to i...
Other Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
Medicine Products: